Novartis turns down Idenix's lead HCV candidate
This article was originally published in Scrip
Executive Summary
Novartis has decided not to exercise its option to license Idenix Pharmaceuticals' lead hepatitis C candidate IDX184. Idenix intends to continue developing the liver-targeted prodrug of 2'-methyl guanosine nucleotide, and is seeking a new partner for the programme.